The FDA imposed a partial clinical hold on an ongoing Phase II study of Vertex Pharmaceuticals Inc.'s hepatitis C virus candidate, VX-135, due to observations of elevated liver enzymes in patients receiving a 400-mg dose of the drug in the trial.